re.Mind Capital

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

Precision Neuroscience, founded in 2021 and based in New York, develops next-generation brain-computer interface technology aimed at treating neurological illnesses. The company's platform is designed to be minimally invasive and safely removable, with the capability to process large amounts of data. This technology enables direct connection between the human brain and artificial intelligence, offering potential breakthrough treatments for the one billion patients worldwide affected by neurological conditions.

Founded in 2021, Sensorium Therapeutics is a Boston-based company developing novel FDA-approved psychoactive medicines using its proprietary drug discovery platform. The platform employs artificial intelligence and computational methods to accelerate the identification of new drug candidates for treating brain and mental health conditions.

iLoF develops an AI-powered digital health platform that accelerates personalized drug discovery. It uses advanced photonics to collect data, building a digital library of biomarkers for studying tailored treatments and making clinical trials more efficient.

Alena is a healthcare application developer that utilizes neuroscience-based games to evaluate user behavior and identify thinking patterns linked to mental health disorders. Founded in 2019 in London, the company combines insights from computational neuroscience and psychiatry to enhance user understanding and treatment options. Its application offers a unique approach that merges evidence-based therapy with innovative techniques to address social anxiety and other mental health challenges. By dynamically adapting to users' evolving needs, Alena aims to facilitate effective stress management and help users overcome anxiety, thereby improving overall mental well-being.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

OccamzRazor develops an AI-powered platform for neuroscience drug discovery and development. It combines machine learning with first-in-class biological techniques to integrate unstructured biomedical text with structured data such as genomics, proteomics and phenomics, generating stronger hypotheses for target identification and drug repurposing. The company's technology analyzes diverse data sources to construct a comprehensive knowledge graph that captures all known information about Parkinson's disease, enabling clinicians and researchers to derive downstream therapeutic insights and to guide strategic drug development.

CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.

OpenBCI is a pioneering open-source platform offering low-cost, programmable EEG hardware for brain-computer interfacing. It empowers researchers and enthusiasts by providing adjustable hardware setups and direct control over signal processing techniques. OpenBCI aims to accelerate innovation in brain science through collaborative development, fostering a community of scientists, engineers, and makers.

Kadence Bio is a clinical-stage life sciences company developing novel therapeutics, with a focus on small molecule programs addressing sexual and mental well-being. Its lead compound KH-001 is being developed as a treatment for premature ejaculation, reflecting the company’s aim to provide additional options for patients and expand therapeutic opportunities in areas with significant unmet need.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

TRIPP is a digital wellness company that develops immersive experiences for virtual reality, augmented reality, and mobile devices to support emotional well-being. The platform combines mindfulness structures, sound frequencies, visuals, and interactive elements to influence mood—helping users feel calmer, more focused, and less stressed. Aimed at consumer households, TRIPP delivers these experiences through VR, AR, and mobile formats, grounded in research-based content. The company is headquartered in Los Angeles, California, with a satellite development office in Chicago.

Founded in 2019, Ksana Health specializes in digital mental health solutions. Its platform collects user data related to mental health and facilitates its transfer to healthcare practitioners for improved patient care.

Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.

Blackrock Neurotech develops advanced neurotechnology platforms for recording bio-potentials from the central and peripheral nervous system. Its precision electrode technology enables innovative brain-computer interfaces, facilitating advancements in neural signal processing and stimulation to improve human lives through clinical applications.

CB Therapeutics is a biotechnology company that develops biosynthetic production of cannabinoids from sugar, using yeast to produce cannabinoids such as CBD and THC without plant material. The company aims to enable next-generation production of cannabinoids and related psychedelic medicines and analogs through a cellular agriculture platform, supporting clinical research and exploration of treatments for mental health conditions and other diseases.